Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, reports the findings of an interim analysis of the UVEA-IXA study of ixazomib-based therapy in relapsed/refractory multiple myeloma. The study enrolled 359 patients and treated them outside the clinical trial setting. Of 275 patients with evaluable outcome data, the overall response rate (ORR) was 60%. Commonly reported adverse effects were in line with those well characterized for ixazomib and were manageable. The data show that ixazomib-based therapy is an effective option in the real-world setting, agreeing with the findings of ixazomib in clinical trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.